Urology Times, Digital Edition, January 2013

One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.

A limited market release of SpaceOAR Flex is expected to begin in the US later this year.

The PDUFA target action date is in the fourth quarter of 2026.

The approval is supported by data from the phase 3 LITESPARK-011 trial.

Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.

Positive safety and efficacy data from 4 clinical studies supported the CE marking.

Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.

In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.